Company Overview - Bristol Myers Squibb is one of the world's largest pharmaceutical companies, known for its long and successful track record in a highly competitive sector with high drug development costs [2] - The company is currently focusing on cardiovascular, cancer, and immune-related medicines, which are significant healthcare opportunities, despite the market's current fascination with GLP-1 weight-loss drugs [4] Financial Performance - The stock is approximately 25% below its late 2022 highs, presenting a potential recovery opportunity alongside a dividend yield of 4%, which is above the average pharmaceutical stock yield of 1.7% [5] - The payout ratio for dividends is around 70%, indicating a sustainable dividend policy, as the company has a history of regularly increasing dividends and maintaining them during tough times [5] - Key financial metrics include a market cap of $127 billion, a gross margin of 65.89%, and a current stock price of $62.37, with a day's range of $61.18 to $62.67 [6][7] Patent and Product Pipeline - Bristol Myers Squibb's Opdivo cancer drug is set to lose patent protection in 2028, raising investor concerns; however, the company is exploring alternative delivery methods to potentially extend patent protections [7] - The company has a pipeline of other drugs in development, demonstrating its ability to manage patent expirations, which are a normal aspect of the pharmaceutical business [8] Investment Opportunity - The current market conditions present an opportunity to invest in an out-of-favor stock with a relatively high yield, allowing for potential growth through dividend reinvestment [9] - While Bristol Myers Squibb should not be the sole investment, it can serve as a strong foundation for a diversified portfolio, enabling investors to take on more risk in other areas [9]

5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever - 24/7 Wall St.[S&P 5006,919.80 +0.42%] [Dow Jones49,382.90 +0.44%][Nasdaq 10025,095.40 +0.46%][Russell 20002,672.51 +0.79%][FTSE 10010,783.00 +0.64%][Nikkei 22559,570.30 +2.83%][Stock Market Live February 25, 2026: S&P 500 (SPY) Up on Trump and Tech][Investing]# 5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever### Quick ReadThe Social Security cost-of-living adjustment (COLA) for 2026 was just 2.8%.The COLA for this year worked o ...

Group 1 - The New York Stock Exchange (NYSE) announced that MSCI Emerging Markets Index Options and MSCI EAFE Index Options will begin trading on NYSE Arca Options under the ticker symbols MXEF and MXEA [1] - Canva has acquired MangoAI and Cavalry to enhance its professional creative suite and AI capabilities [1] - Dynatrace's CEO Rick McConnell will announce the company's achievement of surpassing $1 billion in lifetime AWS Sales during an NYSE Live event [1] Group 2 - Equities are reported to be higher as Nvidia prepares to release its fourth quarter earnings after market close [1] - Americares emphasized the importance of increasing access to healthcare in its recent communications [1] - Bristol-Myers Squibb is holding its annual meeting of top 100 global leaders [1]

Core Viewpoint - The pharmaceutical industry is facing significant challenges due to patent expirations, particularly impacting Bristol Myers Squibb, which is experiencing a steep patent cliff that is affecting its stock performance [1][2][4]. Patent Cliff Impact - Bristol Myers Squibb's stock is down over 25% from its peak due to the impending patent expirations of key drugs, leading to a potential decline in sales [2][4]. - The company anticipates a 48.9% drop in Revlimid sales to $2.9 billion and a 61.7% decrease in Sprycel sales to $493 million by 2025 [4]. - The patents for top-selling drugs Eliquis and Opdivo will expire between 2027 and 2029, which together generated $24.4 billion in sales in 2025, approximately half of the company's total revenue [4]. Growth Potential - Excluding Opdivo, Bristol Myers Squibb's growth portfolio saw a 23% increase in sales, reaching $16.3 billion in 2025 [5]. - Cobenfy, a new antipsychotic drug for schizophrenia, is in phase 3 trials for Alzheimer's-related psychosis, with potential annual sales of $3.4 billion by 2030 if approved [5]. Financial Metrics - Bristol Myers Squibb has a market capitalization of $124 billion, with a current stock price of $60.66 and a dividend yield of 4.10% [6][7]. - Analysts project a decline in total sales from $48.2 billion in 2025 to $45.2 billion by the end of 2027, with earnings expected to remain flat in 2026 [7][8]. Investment Considerations - The current dividend is considered safe, costing less than half of the company's earnings, which may provide stability during business contractions [8]. - The stock is trading at less than 10 times this year's earnings estimates, reflecting the market's awareness of the patent cliff [8]. - If Cobenfy succeeds, it could offset the lost sales from Eliquis and Opdivo, potentially leading to business growth and a rise in stock valuation [9].

Core Insights - Merck & Co. (MRK) and Bristol Myers Squibb (BMY) are significant players in the pharmaceutical industry with diverse product portfolios [1][2] - Merck is recognized for its leadership in oncology, while Bristol Myers focuses on breakthrough therapies across multiple therapeutic areas [1][2] Merck (MRK) Overview - Merck has over six blockbuster drugs, with Keytruda accounting for 54% of total sales in 2025, driving revenue growth [3][4] - Keytruda's sales increased by approximately 7% in 2025, benefiting from its approval for various oncology indications [4] - The FDA approved Keytruda Qlex for subcutaneous administration in September 2025, with peak sales targeted at $35 billion by 2028 [5] - Other oncology drugs like Welireg, Lynparza, and Lenvima are contributing to growth, alongside a strong launch of Winrevair in pulmonary arterial hypertension [6] - Merck is enhancing its vaccine portfolio, particularly with the new 21-valent pneumococcal conjugate vaccine, Capvaxive [7] - The company has around 80 ongoing late-stage studies, expecting over $70 billion in potential commercial opportunities by the mid-2030s [8] Bristol Myers Squibb (BMY) Overview - BMY's growth portfolio includes key brands such as Opdivo, Yervoy, and Reblozyl, with a strong oncology focus [12] - Opdivo's consistent label expansion has maintained its momentum, and the approval of Opdivo Qvantig has strengthened its franchise [13] - BMY's Reblozyl sales exceed $2 billion annually, and strong performance in cardiovascular drug Camzyos has boosted revenues [14] - However, legacy drugs face significant generic competition, with expected sales declines of 12-16% in 2026 [15] - BMY is pursuing strategic acquisitions and collaborations, including a recent agreement with BioNTech to co-develop a bispecific antibody [16][17] - The company aims for $2 billion in annualized cost savings by the end of 2027, having achieved approximately $1 billion in savings in 2025 [18] Financial Performance and Valuation - MRK's 2026 sales are estimated to increase by 2.59%, but EPS is expected to decline by 38.75% [20] - BMY's 2026 sales are projected to decrease by 2.32%, while EPS is expected to increase by 0.33% [20] - MRK shares trade at 21X forward earnings, while BMY trades at 9.74X, with the industry average at 18.74X [24] - BMY offers a higher dividend yield of 4.22% compared to MRK's 2.79% [25] Investment Outlook - BMY is currently viewed as a stronger near-term investment option compared to MRK, which faces multiple headwinds [9][30] - BMY's strategic initiatives and new drug approvals position it favorably against MRK's challenges, including declining sales of Gardasil and competitive pressures on Keytruda [27][30]

Group 1 - Bristol-Myers Squibb Company (NYSE: BMY) has been recognized as a significant winner in the pharmaceutical sector since a strong buy rating was issued in late October, attributed to its successful execution of strategies [1] - The focus is on analyzing undervalued and disliked companies or industries with strong fundamentals and good cash flows, particularly in sectors like Oil & Gas and consumer goods [1] - Energy Transfer is highlighted as a company that was previously overlooked but has shown potential, indicating a long-term value investing approach [1] Group 2 - The article emphasizes a preference for long-term value investing while acknowledging occasional interest in deal arbitrage opportunities, such as those involving Microsoft/Activision Blizzard and Spirit Airlines/Jetblue [1] - There is a clear aversion to investing in businesses that are not well understood, particularly in high-tech and certain consumer goods sectors [1] - The article expresses skepticism towards cryptocurrencies, indicating a focus on more traditional investment avenues [1]

Bristol-Myers Squibb Company ( BMY ) shares have risen 27.7% since my last article , "Why Bristol-Myers Squibb Remains Undervalued In 2025," in mid-November. They have outperformed the S&P 500 [3.6% return] ( SPY ) during that time.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, techno ...

Bristol-Myers Squibb Company ( BMY ) shares have risen 27.7% since my last article , "Why Bristol-Myers Squibb Remains Undervalued In 2025," in mid-November. They have outperformed the S&P 500 [3.6% return] ( SPY ) during that time.With over two decades of dedicated experience in investment, Allka Research has been a guiding force for individuals seeking lucrative opportunities. Its conservative approach sets it apart, consistently unearthing undervalued assets within the realms of ETFs, commodities, techno ...

Core Insights - Bristol Myers Squibb (BMY) has received FDA acceptance for the new drug application (NDA) of iberdomide, in combination with daratumumab and dexamethasone, for treating relapsed or refractory multiple myeloma (RRMM) [1][7] - The FDA has granted a priority review for the NDA, with a decision expected on August 17, 2026 [1] - Iberdomide is part of a new class of drugs known as cereblon E3 ligase modulators (CELMoDs), which are under investigation for RRMM treatment [2][8] BMY's Price Performance - Over the past six months, BMY shares have increased by 24.8%, outperforming the industry average rise of 21.4% [3] Iberdomide Development - The NDA filing is based on data from the phase III EXCALIBER-RRMM study, which showed a statistically significant improvement in minimal residual disease (MRD) negativity rates compared to the control arm [4][7] - The study is ongoing, with patients being assessed for progression-free survival [5] Regulatory Designations - Iberdomide has received Breakthrough Therapy designation from the FDA for the treatment of RRMM [2][7] - The review process is part of the FDA's Project Orbis initiative, allowing simultaneous evaluation by regulatory authorities in other countries [8] Strategic Focus - The successful development of iberdomide and other key pipeline candidates is crucial for Bristol Myers as it aims to expand and diversify its portfolio amid challenges from generic competition [9]

Core Insights - Bristol Myers Squibb's (BMY) revenue performance in 2025 shows a transition with growth from new products offsetting declines in legacy drugs [1][9] - Total revenues were flat year over year, with a 17% increase in sales from the growth portfolio and a 15% decline in legacy products due to generic competition [1][9] Legacy and Growth Portfolio - The legacy portfolio, including drugs like Eliquis, Revlimid, Pomalyst, Sprycel, and Abraxane, is under pressure due to loss of exclusivity for four drugs [2] - The growth portfolio, featuring drugs such as Opdivo, Opdivo Qvantig, Orencia, and others, is crucial for maintaining revenue stability [2] Immuno-Oncology and Key Drug Performance - The immuno-oncology (IO) portfolio, particularly Opdivo, continues to show strong sales momentum due to label expansions and market share growth [3] - Opdivo Qvantig's approval has contributed to growth, with robust initial uptake across approved tumor types in the U.S. [4] - Reblozyl has achieved an annualized sales run rate above $2 billion, while Breyanzi has surpassed $1 billion in annualized sales [5] Future Outlook and Competition - Management anticipates a further decline of 12-16% in legacy sales for 2026, guiding revenues to $46.0-$47.5 billion [7] - BMY faces increasing competition in oncology from companies like Merck, particularly with the success of Keytruda [8][10] Market Performance and Valuation - BMY's shares have gained 12.7% over the past year, compared to the industry's growth of 19.6% [13] - The company is trading at a price/earnings ratio of 9.80x forward earnings, which is lower than the large-cap pharma industry's average of 18.82x [14] Earnings Estimates - The Zacks Consensus Estimate for 2026 EPS has increased to $6.15 from $6.04, while the estimate for 2027 has risen to $5.94 [17]